Arthneeti
ST

Sunita Tools Ltd

Q1 FY27Industrial Manufacturing

Sunita Tools Ltd Q1 FY27 Results & Presentation Highlights: Revenue, Margins & Order Book

Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.

Price₹1,141
Market cap₹670 Cr
P/E102.9
Updated24 Sept 2026
Read4 min read

Based on Sunita Tools Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

The presentation does not provide explicit quarterly revenue or sales figures or volume data. The presentation reports EBITDA figures for FY26 to FY29, not specifically by quarter: - FY26 EBITDA: INR 10 Cr - FY27 EBITDA: INR 45 Cr - FY28 EBITDA: INR 89 Cr - FY29 EBITDA: INR 191 Cr - Operating margin or explicit margin percentages are not directly stated in the presentation.

From Sunita Tools Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • The presentation does not provide explicit quarterly revenue or sales figures or volume data.
  • Projected sales revenue (in INR Cr) for financial years are:
  • FY26: 46 Cr
  • FY27: 161 Cr
  • FY28: 309 Cr
  • FY29: 636 Cr
  • The investor presentation mentions production capacity:
  • Line 1: 10,000 artillery shells per month (120,000 per annum) ready in FY26.
  • Line 2: Planned capacity of 20,000 shells per month (240,000 p.a.), procurement underway.
  • No specific year-on-year quarter-over-quarter growth numbers provided.
  • Explicit outlook indicates strong growth with sales expected to increase substantially over FY26-FY29, more than 10X revenue growth.

2 more points management made on revenue & sales performance

Profitability & Margins

See what Sunita Tools Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Capex for Line 2 artillery shell production planned; procurement under execution as of June 2025 (Page 12).
  • Line 1 artillery shell production at Faridabad is ready for production as of 2026, with 10,000 units/month capacity (Page 12, 8).
  • Line 2 to produce 20,000 units/month, planned capacity 2,40,000 shells p.a. (Page 12).
  • Capex and installation of machinery at factory to manufacture artillery shells started June 2025; successful machine running trials in Sept 2025 (Page 8).
  • Acquisition of New Mould Innovations (NMI), Kentucky, USA, completed, manufacturing aerospace-grade grease and patented cartridges (Page 12, 9).

2 more points management made on capital expenditure plans

Top-ranked in Industrial Manufacturing

Ranked on what management guided this quarter

5x potential
1ICE Make Refrig.
Rev 1Mar 2
2Taurian MPS
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Sunita Tools Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly state the order book, order inflow, or pending orders in exact figures or detailed terms. It primarily highlights: - Installed production capacity of 10,000 artillery shells per month in Line 1 (120,000 shells p.a.). - Planned Line 2 with capacity for 20,000 artillery shells per month (240,000 shells p.a.) with procurement underway. - Focus on exports and Atmanirbhar Bharat initiative.

2 more points management made on order book & pipeline

Continue your research

What Sunita Tools Ltd's management said in earlier quarters

Others in Industrial Manufacturing this season

  • Merritronix (Q1 FY27)

    Revenue from operations (₹ Lakhs): . Key investor presentation takeaways from Merritronix Ltd's Q1 FY27 investor presentation — and how it ranks against sector

  • Bajaj Steel Inds (Q1 FY27)

    Q1 FY27 Revenue from Operations: Rs 120.4 Cr . Key investor presentation takeaways from Bajaj Steel Industries Ltd's Q1 FY27 investor presentation — and how it

  • Lokesh Mach. (Q1 FY27)

    Revenue from operations for Q1 FY27: ₹55.46 crore, up 15.4% YoY (Q1 FY26: ₹48.32 crore) [Page 4] . Key investor presentation takeaways from Lokesh Machines Ltd'

  • Windsor Machines (Q1 FY27)

    Q1FY27 Revenue from Operations: ₹148.9 Cr, up 31.4% YoY (Q1FY26: ₹113.3 Cr). Key investor presentation takeaways from Windsor Machines Ltd's Q1 FY27 investor pr

Compare:vs Mazagon Dockvs Indo-MIMvs Aditya Infotech

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Sunita Tools Ltd Q1 FY27 results?

The presentation does not provide explicit quarterly revenue or sales figures or volume data. The presentation reports EBITDA figures for FY26 to FY29, not specifically by quarter: - FY26 EBITDA: INR 10 Cr - FY27 EBITDA: INR 45 Cr - FY28 EBITDA: INR 89 Cr - FY29 EBITDA: INR 191 Cr - Operating margin or explicit margin percentages are not directly stated in the presentation.

What is Sunita Tools Ltd share price analysis?

Sunita Tools Ltd currently shows a neutral. The stock trades at a P/E of 102.9 with a market cap of ₹670 Cr. Investors should review the full earnings analysis for detailed insights.

Is Sunita Tools Ltd planning capital expenditure?

Capex for Line 2 artillery shell production planned; procurement under execution as of June 2025 (Page 12). - Line 1 artillery shell production at Faridabad is ready for production as of 2026, with 10,000 units/month capacity (Page 12, 8). - Line 2 to produce 20,000 units/month, planned capacity 2,40,000 shells p.a.

Keep Sunita Tools Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.